P
Philippe Follana
Researcher at Institut Gustave Roussy
Publications - 56
Citations - 3831
Philippe Follana is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 16, co-authored 39 publications receiving 2806 citations.
Papers
More filters
Journal ArticleDOI
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mansoor Raza Mirza,Bradley J. Monk,Jørn Herrstedt,Amit M. Oza,Sven Mahner,Sven Mahner,Andrés Redondo,Michel Fabbro,Jonathan A. Ledermann,Domenica Lorusso,Ignace Vergote,Noa Ben-Baruch,Christian Marth,Radosław Mądry,René dePont Christensen,Jonathan S. Berek,Anne Dørum,Anne Dørum,Anna V. Tinker,Andreas du Bois,Antonio González-Martín,Philippe Follana,Benedict B. Benigno,Per Rosenberg,Lucy Gilbert,Bobbie J. Rimel,Joseph Buscema,John Balser,Shefali Agarwal,Ursula A. Matulonis,Ursula A. Matulonis +30 more
TL;DR: Among patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progression-free survival was significantly longer amongThose receiving niraparib than among those receiving placebo, regardless of the presence or absence of gBRCA mutations or HRD status, with moderate bone marrow toxicity.
Journal ArticleDOI
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Eric Pujade-Lauraine,Felix Hilpert,Béatrice Weber,Alexander Reuss,Andreas Poveda,Gunnar B. Kristensen,Roberto Sorio,Ignace Vergote,Petronella O. Witteveen,Aristotelis Bamias,Deolinda Pereira,Pauline Wimberger,Ana Oaknin,Mansoor Raza Mirza,Philippe Follana,David T. Bollag,Isabelle Ray-Coquard +16 more
TL;DR: Adding bevacizumab to chemotherapy statistically significantly improved PFS and ORR; the OS trend was not significant.
Journal ArticleDOI
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
Josep M. del Campo,Ursula A. Matulonis,Susanne Malander,Diane Provencher,Sven Mahner,Philippe Follana,Justin Waters,Jonathan S. Berek,Kathrine Woie,Amit M. Oza,Ulrich Canzler,M. Gil-Martin,Anne Lesoin,Bradley J. Monk,Bente Lund,Lucy Gilbert,Robert M. Wenham,Benedict B. Benigno,Sujata Arora,Sebastien Hazard,Mansoor Raza Mirza +20 more
TL;DR: Progression-free survival was improved in patients treated with niraparib compared with placebo in both the gBRCAmut cohort and the non–gBRC amut cohort, and no meaningful differences were observed between nirAParib and placebo in PR and CR subgroups with respect to patient-reported outcomes.
Journal ArticleDOI
Free‐Flap Head and Neck Reconstruction and Quality of Life: A 2‐Year Prospective Study
Alexandre Bozec,Gilles Poissonnet,Emmanuel Chamorey,Cédric Casanova,Jacques Vallicioni,François Demard,P Mahdyoun,Frederic Peyrade,Philippe Follana,René-Jean Bensadoun,Karen Benezery,Juliette Thariat,Pierre-Yves Marcy,Anne Sudaka,Olivier Dassonville +14 more
TL;DR: This prospective study was designed to evaluate quality of life after free‐flap head and neck reconstruction and found no significant differences between men and women after the two types of reconstruction.
Journal ArticleDOI
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
Xavier Pivot,Gilles Romieu,Marc Debled,Jean-Yves Pierga,Pierre Kerbrat,Thomas Bachelot,Alain Lortholary,Marc Espié,P. Fumoleau,Daniel Serin,Jean-Philippe Jacquin,Christelle Jouannaud,Maria Rios,Sophie Abadie-Lacourtoisie,Laurence Venat-Bouvet,Laurent Cany,Stéphanie Catala,David Khayat,Laetitia Gambotti,Iris Pauporté,Céline Faure-Mercier,Sophie Paget-Bailly,Julie Henriques,Jean-Marie Grouin,C Piprot,L. Cals,Loic Chaigneau,F Demarchi,T N'Guyen,U Stein,Cristian Villanueva,Jean Luc Breau,AK Chouahnia,Pierre Saintigny,F Boué,P deSaint-Hilaire,I Guimont,Nathalie Grossat,B Valenza,E. Levy,J. Medioni,C Delbaldo,J. Grenier,Damien Pouessel,Sandrine Lavau-Denes,Claire Falandry,Cécile Fournel-Federico,Gilles Freyer,Sophie Tartas,Véronique Trillet-Lenoir,F Bons,G Auclerc,S Chièze,N. Raban,Christophe Tournigand,S Trager-Maury,Guilhem Bousquet,C Cuvier,Sylvie Giacchetti,A Hocini,C. Lemaignan,J-L Misset,D. Avenin,C Beerblock,Joseph Gligorov,P. Rivera,H. Roche,Philippe Bougnoux,N Hajjaji,Olivier Capitain,Remy Delva,P. Maillart,Patrick Soulié,H. Bonnefoi,M. Durand,N. Madranges,Louis Mauriac,Philippe Chollet,Anne-Françoise Dillies,Xavier Durando,Jean-Pierre Ferriere,C Mouret-Reynier,Jean-Marc Nabholtz,I. van Praagh,Pietrina Cottu,Véronique Diéras,A Durieux,M Galotte,Veronique Girre,Stéphanie Henry,Ida Iurisci,M. Jouve,V Laurence,L. Mignot,S. Piperno-Neumann,P. Tresca,Bruno Coudert,E Ferrant,Frank Mayer,AC Vanneuville,Jacques Bonneterre,V Servent,L. Vanlemmens,P Vennin,Jean-Paul Guastalla,Pierre Biron,L Dupuy-Brousseau,L Lancry,I. Ray-Coquard,Paul Rebattu,Olivier Tredan,Jean-Marc Extra,F Rousseau,Carole Tarpin,Michel Fabbro,Elisabeth Luporsi,L. Uwer,Bettina Weber,Dominique Berton-Rigaud,Emmanuelle Bourbouloux,M. Campone,J-M Ferrero,Philippe Follana,Rémy Largillier,Véronique Mari,B Costa,Hervé Curé,Jean-Christophe Eymard,Nicolas Jovenin,D. Lebrun,Jérôme Meunier,G Yazbek,D Gedoin,Brigitte Laguerre,Claudia Lefeuvre,E Vauléon,A Chevrier,Cécile Guillemet,Marianne Leheurteur,O Rigal,Isabelle Tennevet,Corinne Veyret,E. Brain,M Guiterrez,F Mefti-Lacheraf,T. Petit,F. Dalenc,Laurence Gladieff,Fabrice Andre,Suzette Delaloge,Julien Domont,J. Ezenfis,M. Spielmann,P Guillet,V Boulanger,Judith L. Provencal,Laetitia Stefani,C Alliot,D Ré,C Bellaiche-Miccio,G Boutan-Laroze,R Vanica,P Dion,G Sadki-Benaoudia,A Marti,Anne-Laure Villing,B Slama,Jean-Luc Dutel,S Nguyen,R Saad,Olivier Arsene,Z Merad-Boudia,H. Orfeuvre,J. Egreteau,M J Goudier,R. Lamy,B. Leduc,Corinne Sarda,Bernard Salles,Cécile Agostini,Isabelle Cauvin,Armelle Dufresne,M Mangold,S. Lebouvier-Sadot,B Audhuy,Jean-Claude Barats,S Cluet-Dennetière,D. Zylberait,G Netter,L. Gautier-Felizot,Isabelle Cojean-Zelek,Anne Plantade,Stéphane Vignot,E. Guardiola,P Marti,I deHartingh,R Diab,A Dietmann,S Ruck,C Portois,S. Oddou-Lagraniere,F Campos-Gazeau,A Bourcier,Frank Priou,J.-F. Geay,D. Mayeur,P Gabez,R ElAmarti,Martin Combe,P Raichon-Patru,P Amsalhem,Jérôme Dauba,D. Paraiso,F. Guinet,Bernard Duvert,M Litor,F Kara-Slimane,A Bichoffe,N Denizon,P Soyer,François Morvan,S Van-Hulst,Lionel Vincent,Caroline Alleaume,P Ibanez-Martin,A Youssef,Z Tadrist,E. Carola,C Pourny,JF Toccanier,N Al-Aukla,K Mahour-Bacha,J. Salvat,P. Nouyrigat,S. Clippe,Marie-Claude Gouttebel,Lionel Vedrine,G Clavreul,Olivier Collard,D. Mille,Y Goubely,Robert Herve,S Kirscher,F Plat,Valérie Delecroix,V Ligeza-Poisson,David Coeffic,D Fric,C Garnier,Cécile Leyronnas,T Kreitman,E Teissier,Pierre-Marie Martin,S Rohart deCordoue,C ElKouri,Jean-François Ramée,C Laporte,O. Bernard,T Altwegg,Ariane Darut-Jouve,JP Dujols,F Darloy,C. Giraud,V Pottier-Kyndt,N Achour,S Drony,M Moriceau,C Sarrazin,JC Legueul,J Mandet,D. Besson,Anne-Claire Hardy-Bessard,J. Cretin,P Houyau,E Achille,Dominique Genet,Henri J. Thevenot,A Moran-Ribon,JM Pavlovitch,P Ardisson,Isabelle Moullet,Bettina Couderc,V Fichet,Fabien Burki,A Auliard,C.-B. Levaché,P Cailleux,F Schaeffer,N Albin,D. Sevin-Robiche,J Domas,S Ellis,P Montcuquet,GA Baumont,M Bégue,S Gréget,JL Ratoanina,A Vanoli,C Bielsa,M Bonichon-Lamichhane,Dominique Jaubert,H. Laharie-Mineur,L Alcaraz,Eric Legouffe,Hugues Bourgeois,Guillaume Cartron,Fabrice Denis,O. Dupuis,G. Ganem,S Roche-Forestier,L Delzenne,E Chirat,JL Baticle,E Béguier,S. Jacquot,E. Janssen,H Lauché,A LeRol,JP Chantelard,GA L'Helgoualc'h,Eric-Charles Antoine,A Kanoui,JF Llory,JM Vannetzel,J Vignoud,C Bruna,Thomas Facchini,K Moutel-Corviole,A Voloch,Aïda Ghoul,D Loiseau,N Barbet,N. Dohollou,K Yakendji +333 more
TL;DR: No change in the cardiac safety comparison, and only three additional cases in which the left ventricular ejection fraction decreased to less than 50% have been reported in the 12-month group, means adjuvant trastuzumab standard duration should remain 12 months.